Elvucitabine

From Wikipedia, the free encyclopedia

Elvucitabine

Systematic (IUPAC) name
4-amino-5-fluoro-1-[(2S,5R)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2-one
Clinical data
Legal status	?
Identifiers
CAS number	181785-84-2^Y
ATC code	None
PubChem	CID 469717
UNII	M09BUF90C0^Y
ChEMBL	CHEMBL38700^N
NIAID ChemDB	060327
Chemical data
Formula	C₉H₁₀F N₃O₃
Mol. mass	227.19 g/mol
N (what is this?) (verify)

Elvucitabine is an experimental nucleoside reverse transcriptase inhibitor (NRTI), developed by Achillion Pharmaceuticals, Inc. for the treatment of HIV.

Currently, it is in Phase II clinical trials.^[1]

References

↑ "Elvucitabine". AIDSmeds.com. November 5, 2007. Retrieved March 21, 2008.

Antiviral drugs: antiretroviral drugs used against HIV (primarily J05)

Entry/fusion inhibitors
(Discovery & development)

gp41 (Enfuvirtide)
CCR5 (Maraviroc
Vicriviroc^†, Cenicriviroc^†, PRO 140^†)
CD4 (Ibalizumab^†)

Reverse-transcriptase
inhibitors (RTIs)

Nucleoside & nucleotide (NRTI)	Nucleoside analogues/NARTIs: Abacavir (ABC)°^# Emtricitabine (FTC)°^# Lamivudine (3TC)°^# Didanosine (ddI)^# Zidovudine (AZT)^# Apricitabine^† Stampidine^† Elvucitabine^† Racivir^† Amdoxovir^† Stavudine (d4T)^# Zalcitabine (ddC)^◊ Festinavir^† Nucleotide analogues/NtRTIs: Tenofovir disoproxil fumarate (TDF)°^# Tenofovir alafenamide fumarate (TAF)^†

Non-nucleoside (NNRTI) (Discovery & development)	(1st generation) Efavirenz (EFV)°^# Nevirapine (NVP)^# Loviride^◊ Delavirdine (DLV)^◊ (2nd generation) diarylpyrimidines (Etravirine Rilpivirine) Lersivirine^†

Integrase inhibitors

Maturation inhibitors

Bevirimat^†

Protease Inhibitors (PI)
(Discovery and development)

1st generation	Fosamprenavir° Lopinavir°^# Nelfinavir^# Ritonavir^# Saquinavir^# Amprenavir^◊ Indinavir^◊^#

2nd generation	Atazanavir° Darunavir° Tipranavir

Combined formulations

Experimental agents

Uncoating inhibitors	TRIM5alpha (gene)

Transcription inhibitors	Tat antagonists

Translation inhibitors	Trichosanthin

Other	Abzyme Calanolide A Ceragenin Cyanovirin-N Diarylpyrimidines Epigallocatechin gallate (EGCG) Foscarnet Griffithsin Hydroxycarbamide Miltefosine Portmanteau inhibitors Seliciclib^† Synergistic enhancers Tre recombinase Zinc finger protein transcription factor KP-1461^† Cobicistat^†

Failed agents	Dexelvucitabine Capravirine Emivirine Lodenosine Atevirdine Brecanavir Aplaviroc

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

°DHHS preferred first-line agent. ^◊Formerly or rarely used agent.

M: VIR

virs(prot)/clss

cutn/syst (hppv/hiva, infl/zost/zoon)/epon

drug (dnaa, rnaa, rtva, vacc)

This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.